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In this article we estimate confidence regions of the common measures of (baseline, treatment 
effect) in observational studies, where the measure of baseline is baseline risk or baseline odds 
while the measure of treatment effect is odds ratio, risk difference, risk ratio or attributable 
fraction, and where confounding is controlled in estimation of both baseline and treatment 
effect. To avoid high complexity of the normal approximation method and the parametric or 
non-parametric bootstrap method, we obtain confidence regions for measures of (baseline, 
treatment effect) by generating approximate distributions of the ML estimates of these 
measures based on one logistic model.   
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1 Introduction 
Suppose that one conducts a randomized trial to investigate the effect of a dichotomous 
treatment z on a dichotomous outcome y of certain population, where 𝑧 = 0, 1 indicate the 
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active respective control treatments while 𝑦 = 0, 1 indicate positive respective negative 
outcomes. With a sufficiently large sample, covariates are essentially unassociated with 
treatments z and thus are not confounders. Let R𝑧 =  pr(𝑦 =  1 |𝑧) be the risk of 𝑦 = 1 given 
z. Then R𝑧 is marginal with respect to covariates and thus conditional on treatment z only, so R𝑧 is also called marginal risk. One can use R𝑧 to obtain the measures of baseline and 
treatment effect which are called marginal measures. The comment measures of baseline are 
the baseline risk  R0 =  pr(𝑦 =  1 |𝑧 = 0) and the baseline odds O0 = R0/(1 − R0).  
 
The common measures of treatment effect are the odds ratio 
OR = O1O0 
where O𝑧 = R𝑧/(1 − R𝑧) is the odds under treatment z, and the risk difference 
RD = R1 − R0, 
the risk ratio 
RR = R1R0, 
and the attributable fraction 
AF = 1 − R0R1. 
 
When presenting treatment effect, one also presents baseline in order to learn significance of 
the treatment effect to the population. For instance, RD = − 0.5 % has rather different 
epidemiologic meanings when R0  is 1 % versus 50 %, so one should present both RD and R0. 
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A similar situation occurs in which RR = 0.5 when R0 is 1 % versus 50 %. The common 
measures of (baseline, treatment effect) are (O0, OR) (R0, RD), (R0, RR) and (R0, AF). All 
these measures have causal interpretation in the framework of the Rubin causal model and 
reflect different aspects of the same underlying (baseline, treatment effect) (Rosenbaum and 
Rubin, 1983; Rosenbaum, 1995; Rubin et al., 2009). 
 
Now suppose that one conducts an observational study to investigate the effect of the treatment 
z on the outcome y of the population above and wishes to describe (baseline, treatment effect) 
by the same measures (O0, OR) (R0, RD), (R0, RR) and (R0, AF) as in the randomized trial. 
However, in the observational study, covariates may be associated with both y and z and 
therefore are confounders. In this case, one needs to use the conditional risk pr(𝑦 = 1|𝑧,𝒙) 
given not only z but also x, instead of the marginal risk pr(𝑦 = 1|𝑧), to obtain these measures. 
As a result, it is highly difficult to estimate these measures as described below.  
 
For illustration, consider the case in which there is only one covariate x. To estimate the 
measures (O0, OR) (R0, RD), (R0, RR) and (R0, AF) through  pr(𝑦 = 1|𝑧,𝒙), the most 
common model is logistic model, for instance,  
Log �
pr(𝑦 = 1 | 𝑧, 𝒙)1 − pr(𝑦 = 1 | 𝑧,𝒙)� = α + β 𝑧 + θ𝑥 + 𝛾(𝑧𝑥) 
Here exp(α) is the baseline odds in stratum  𝑧 = 0, 𝑥 = 0; exp(β) is the conditional odds ratio 
describing the treatment effect in stratum 𝑥 = 0. Noticeably, the measures R0, O0, OR, RD, 
RR and AF as parameters of interest are not equal to the model parameters or their 
exponentials and therefore cannot be estimated as parameters of this model. Even if 𝛾 = 0, i.e. 
there is no product term between z and x, the conditional odds ratio exp(β) is not equal to the 
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marginal odds ratio OR; see rich literatures about non-collapsibility of odds ratios (e.g. Gail, 
1984; Greenland et al., 1999; Lee and Nelder, 2004; Austin et al., 2007; Austin, 2007). Also 
see literatures about convertibility and non-convertibility from exp(β) to RR (Greenland, 1987;  
Zhang and Yu, 1998; McNutt et al., 2003; Greenland, 2004a); notice literatures about  linear or 
log-linear models in estimation of RD or RR (Bieler et al., 2010; Spiegelman and Hertzmark, 
2005; Cheung, 2007; Zou, 2004).      
 
On the other hand, one can always express R0, O0, OR, RD, RR and AP in terms of  the 
parameters of a logistic model. The ML estimates of R0, O0, OR, RD, RR and AP can be 
obtained from those of the model parameters.  The usual methods of obtaining the interval 
estimate of treatment effect are the normal approximation method and the bootstrap method 
(Lane and Nelder, 1982; Graubard and Korn, 1999; Greenland, 2004a; Greenland, 2004b; 
Austin, 2010; Gehrmanna et al., 2010). In the normal approximation method, one derives 
approximate variance of the ML estimate of a measure of treatment effect and then uses the 
variance to obtain normal approximation confidence interval for the measure. However, the 
derivation of the variance is tedious and the expressions of the variance are different for 
different logistic models containing different products between z and x. In the bootstrap 
method, one generates bootstrap samples and then uses the bootstrap samples to obtain 
bootstrap distribution and thus the confidence interval of a measure of treatment effect. 
However, it is highly difficult to correct finite-sample bias due to the bootstrap sampling, 
which typically occurs with the asymmetric – i.e. screwed -- distribution of the ML estimate as 
is the case for dichotomous outcome (Davison and Hinkley, 1997; Carpenter and Bithell, 2000; 
Greenland, 2004b).  
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In this article, we use only one logistic model to obtain the confidence regions for all the 
measures (O0, OR), (R0, RD), (R0, RR) and (R0, AP) of (baseline, treatment effect) in 
observational studies. Instead of deriving covariance matrix of the two-dimensional ML 
estimate or correcting the finite-sample bias of the two-dimensional bootstrap sampling, we use 
approximate normal distribution of the ML estimate of the logistic model parameters to 
generate approximate distribution of the ML estimate of a measure of (baseline, treatment 
effect) and then use the obtained distribution to calculate confidence region for this measure.  
 
We are going to present the method through an observational study embedded in a randomized 
trial, in which we investigated the effect of high versus low doses of a therapy on eradication 
of Helicobacter pylori among Vietnamese children. 
 
2 Eradication of Helicobacter pylori among Vietnamese children  
In a randomized trial, researchers studied two triple therapies – (lansoprazole, amoxicillin, 
metronidazole) and (lansoprazole, amoxicillin, clarithromycin) – for their abilities to eradicate 
Helicobacter pylori among Vietnamese children (Nguyen et al., 2008). From several children 
hospitals in Hanoi, restricting body weight to a range between 13 kg and 45 kg, a sample was 
collected between May 2005 and January 2006. In a substudy, researchers focused on one 
treatment arm of the triple therapy (lansoprazole, amoxicillin, metronidazole) and analyzed the 
treatment effect of high versus low doses of the therapy on eradication of Helicobacter pylori. 
The treatment arm comprised 109 patients.   
 
The therapy eradicated Helicobacter pylori through systemic circulation, so the researchers 
assigned the therapy to the children according to their body weights. According to the pediatric 
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procedure, children with 13 kg < body weight < 23 kg received the therapy once daily and 
those with 23 kg ≤ weight < 45 kg twice daily. Of medical relevance was dose in unit body 
weight. Following the earlier research on the same data, we categorized the children into 
receiving high versus low doses of the therapy by taking the middle point of each weight 
category as the threshold (Nguyen et al., 2008). Hence children with 13 kg < body weight ≤18 
kg in the first category and 23 kg ≤ body weight < 34 kg in the second category were 
considered as receiving the high dose (z = 1) of the therapy whereas those with 18 kg < body 
weight < 23 kg in the first category and 34 kg ≤ body weight < 45 kg in the second category as 
receiving the low dose (z = 0).  
 
The outcome was successful (y = 1) versus unsuccessful (y = 0) eradication of Helicobacter 
pylori.  
 
In the context of this substudy, body weight was synonymous to treatment z and thus was not a 
covariate.  The covariate age (x1) was associated with body weight and thus with the 
assignment of treatments z. Furthermore, age was known to have effect on the outcome y and 
thus was a confounder. Therefore this substudy had the nature of an observational study. Other 
possible confounding covariates were documented, which were gender (x2), geographic area 
(x3) and antibiotic resistance to metronidazole (x4). Age was categorized into younger (x1 = 1) 
than 9 years versus older (x1 = 0). Let x2 = 1 indicate female and x2 = 0 male of the gender. 
Geographic area was categorized into rural (x3 = 1) versus urban (x3 = 0). Antibiotic resistance 
to metronidazole was categorized into sensitive (x4 = 1) versus resistant (x4 = 0). Let 𝒙 = (x1, 
x2, x3, x4) be the set of the documented covariates. The data of the substudy is given in Table 1. 
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The conditional risk pr(𝑦 = 1 | 𝑧,𝒙) of 𝑦 = 1 in stratum (𝑧,𝒙) is modeled by logistic model. 
By the likelihood ratio-based significance testing of the model parameters, we obtain 
Log{ pr(𝑦 = 1 | 𝑧,𝒙)1 − pr(𝑦 = 1 | 𝑧, 𝒙)}  = 
α + β 𝑧 + 𝜃1𝑥1 + 𝜃2𝑥2 + 𝜃3𝑥3 + 𝜃4𝑥4 + 𝜃5(𝑧 ∗ 𝑥2) + 𝜃6(𝑧 ∗ 𝑥3).                    (1) 
In addition to the main effect terms for the treatment z and the covariates 𝒙, we include in this 
model two product terms: one  for the treatment--gender (z * x2) and one for the treatment--
geographic area (z * x3), because of the small p-values, 0.10 and 0.11, for the significance test 
of  θ5 = 0 and θ6 = 0 respectively. Let 𝜋 = (𝛼, 𝛽,  𝜃1,  𝜃2 ,  𝜃3,  𝜃4,  𝜃5, 𝜃6) be the set of all the 
model parameters. The ML estimate 𝜋� = (𝛼�, ?̂?,  𝜃�1, 𝜃�2,  𝜃�3,  𝜃�4,  𝜃�5, 𝜃�6) and its approximate 
covariance matrix  Σ� (i.e. the inverse of the observed information) are presented in Table 2.  
 
3 Confidence regions of (baseline, treatment effect) 
 
3.1  Measures of (baseline, treatment effect)  
Here we use the conditional risk pr(𝑦 = 1 | 𝑧,𝒙) to obtain the measures (O0, OR), (R0, RD), (R0, RR) and (R0, AF) of (baseline, treatment effect) introduced in the introduction. Let 𝑦𝑧 be 
the potential outcome of each patient in the population under treatment z = 0, 1. Denote the 
risk pr(𝑦𝑧 = 1) of the potential outcome 𝑦𝑧 = 1 by R𝑧. Then R0 is the baseline risk, i.e. the 
risk of 𝑦𝑧 = 1 in the population under z = 0. 
 
Because it is only possible to observe potential outcome of a patient under either z = 0 or z = 1, 
certain assumption is needed to allow for estimation of R𝑧 (Greenland et al., 1999; Greenland 
and Robins, 1986; Rosenbaum and Rubin, 1983; Rosenbaum, 1995; Rubin et al., 2009). In the 
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medical context of this study, it is reasonable to assume that there is no other confounding 
covariate than the documented covariates 𝒙 (Nguyen et al., 2008). The assumption implies  
 pr(𝑦𝑧 = 1|𝒙) = pr(𝑦 = 1 | 𝑧,𝒙) 
which states that the patients in stratum x, who have not received treatment z, would have the 
same risk pr(𝑦 = 1 | 𝑧,𝒙) as those who have received treatment z, if they had received 
treatment 𝑧. Therefore we can express the risk R𝑧 = pr(𝑦𝑧 = 1) of the potential outcome 
𝑦𝑧 = 1 by 
 R𝑧 = �  pr(𝑦𝑧 = 1|𝒙)pr(𝒙) =
𝒙
�  pr(𝑦 = 1|𝑧,𝒙)pr(𝒙),                                     (2)
𝒙
 
and in particular, the baseline risk R0 by 
R0 = �  pr(𝑦 = 1|𝑧 = 0,𝒙)pr(𝒙),
𝒙
 
where pr(𝒙) is the probability of x in the population.  Formula (2) implies that we can estimate R𝑧 or its function by modeling pr(𝑦 = 1|𝑧,𝒙) and pr(𝒙) through the observed data. 
 
Now we express the measures of baseline and treatment effect in terms of pr(𝑦 = 1|𝑧,𝒙) and 
pr(𝒙). The odds of the population under treatment z has the form  
O𝑧 = R𝑧1 − R𝑧 = ∑ pr(𝑦 = 1 | 𝑧,𝒙)pr(𝒙)𝒙1 − ∑ pr(𝑦 = 1 | 𝑧,𝒙)pr(𝒙)𝒙 ,   𝑧 = 0,1                       (3) 
Hence the baseline odds is 
O0 = R01 − R0 = ∑ pr(𝑦 = 1 | 𝑧 = 0, 𝒙)pr(𝒙)𝒙1 − ∑ pr(𝑦 = 1 | 𝑧 = 0,𝒙)pr(𝒙)𝒙 .                                         (4) 
The odds ratio is 
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OR = O1O0 
= ∑ pr(𝑦 = 1 | 𝑧 = 1, 𝒙)pr(𝒙)𝒙1 − ∑ pr(𝑦 = 1 | 𝑧 = 1,𝒙)pr(𝒙)𝒙  ∑ pr(𝑦 = 1 | 𝑧 = 0,𝒙)pr(𝒙)𝒙1 − ∑ pr(𝑦 = 1 | 𝑧 = 0, 𝒙)pr(𝒙)𝒙� .          (5) 
The risk difference is 




The risk ratio is  RR = R1R0 = ∑ pr(𝑦 = 1 | 𝑧 = 1,𝒙)pr(𝒙)𝒙∑ pr(𝑦 = 1 | 𝑧 = 0,𝒙)pr(𝒙)𝒙 .                                       (7) 
 
 
Finally, the attributable fraction is 
AF=1 − R0R1 = 1 − ∑ pr(𝑦 = 1 | 𝑧 = 0,𝒙)pr(𝒙)𝒙∑ pr(𝑦 = 1 | 𝑧 = 1,𝒙)pr(𝒙)𝒙 .                                 (8) 
 
In particular, in randomized trial, the treatment z is not associated with the covariates x, so that pr(𝒙) = pr(𝒙|𝑧). Insertion of this into (2) yields the risk pr(𝑦 =  1 |𝑧) of 𝑦 = 1 in stratum z, 
R𝑧 = �  pr(𝑦 = 1|𝑧,𝒙)pr(𝒙|𝑧) = pr(y = 1|z)
𝒙
. 
Therefore we see that  R𝑧 and thus R0, O0, OR, RD, RR and AF defined here are equal to those 
defined in the introduction for randomized trial. No matter if it is a randomized trial or an 
observational study, all these measures have causal interpretation in the Rubin causal model 
(Rosenbaum and Rubin, 1983; Rosenbaum, 1995; Rubin et al., 2009).  
 
3.2 Point estimation of (baseline, treatment effect) 
From model (1), we obtain  
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pr(𝑦 = 1 | 𝑧,𝒙) = exp{α + β 𝑧 + 𝜃1𝑥1 + 𝜃2𝑥2 + 𝜃3𝑥3 + 𝜃4𝑥4 + 𝜃5(𝑧 ∗ 𝑥2) + 𝜃6(𝑧 ∗ 𝑥3)}1 + exp{α + β 𝑧 + 𝜃1𝑥1 + 𝜃2𝑥2 + 𝜃3𝑥3 + 𝜃4𝑥4 + 𝜃5(𝑧 ∗ 𝑥2) + 𝜃6(𝑧 ∗ 𝑥3)}.        (9) 
We are going to use (9) to express the measures of baseline and treatment effect in terms of the 
model parameters 𝜋 = (𝛼, 𝛽,  𝜃1,  𝜃2 ,  𝜃3,  𝜃4,  𝜃5, 𝜃6). We shall ignore variability of the 
covariates x, so that we replace the probability pr(𝒙) by the proportion prop(𝒙) and treat the 
proportion as constant.  
 
Inserting pr(𝑦 = 1 | 𝑧,𝒙) of (9) into (2), we obtain R𝑧 (𝑧 = 0,1) as a function of 𝜋, 
R𝑧(𝜋) = �  pr(𝑦 = 1|𝑧,𝒙)prop(𝒙).                                                 (10)
𝒙
 
Inserting pr(𝑦 = 1 | 𝑧,𝒙) of (9) into (3)-(5), we obtain O𝑧 and OR as functions of 𝜋,  
O𝑧(𝜋) = R𝑧(𝜋)1 − R𝑧(𝜋) ,    𝑧 = 0,1                                                   (11) 
OR(𝜋) = O1(𝜋)O0(𝜋)                                                                        (12) 
Similarly, from (6)-(8), we obtain  
RD(𝜋) = R1(𝜋) − R0(𝜋),                                                                  (13) 
 RR(𝜋) = R1(𝜋)R0(𝜋),                                                                           (14) 
 
 AF(𝜋) = 1 − R0(𝜋)R1(𝜋) .                                                                       (15) 
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Replacing 𝜋 in R0(𝜋), O0(𝜋), OR(𝜋), RD(𝜋), RR(𝜋) and AR(𝜋) by the ML estimate 𝜋� given 
in Table 2, we obtain the ML estimates R�0 = R0(𝜋�), O�0 = O0(𝜋�), OR� = OR(𝜋�), RD� = RD(𝜋�), RR� = RR(𝜋�) and AP� = AP(𝜋�). These estimates are R�0 = 0.53, O�0 = 1.13,  OR� = 2.11, RD� = 0.17, RR� = 1.33, and AP� = 0.25, which are also presented in Figures 1-4 and Table 3.  
 
3.3 Distributions for ML estimates of (baseline, treatment effect) 
Parameters of a logistic model have good asymptotic normality: normal distribution is good 
approximation to distribution of the ML estimate of the parameters (e.g. Lindsey, 1996). We 
are going to use the approximate normal distribution of the ML estimate of the model 
parameters to generate approximate distribution of the ML estimates of measures of (baseline, 
treatment effect). 
 
Let p be a random variable which follows the normal distribution N(𝜋� , Σ�), namely, 
𝑝 ~ N(𝜋� , Σ�), where 𝜋� and Σ� in N(𝜋� , Σ�) are given in Table 2. Replacing 𝜋 in {O0(𝜋), OR(𝜋)} by 
p gives {O0(𝑝), OR(𝑝)}. By using the normal distribution of p, we generate the distribution of {O0(𝑝), OR(𝑝)}, which approximates the distribution of (O�0, OR� ). Using the same method, we 
also obtain the approximate distributions of (R�0, RD� ), (R�0, RR� ) and (R�0, AF�) respectively.  
 
3.4 Confidence region estimation of (baseline, treatment effect) 
In this article, the confidence region of a measure of (baseline, treatment effect) is defined as 
the smallest area given a confidence level (1 − 𝛼), i.e. the smallest area in which the ML 
estimate of the measure has the probability (1 − 𝛼). Given the distribution of the ML estimate 
of a measure of (baseline, treatment effect), we can obtain the confidence region of the 
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measure by a variety of methods. Here we are going to obtain confidence regions of (O0, OR), (R0, RD), (R0, RR) and (R0, AP) by using convertibility of these measures.  As will be seen in 
Section 4, this method can be easily implemented by using any software that generates normal 
distribution. 
 
It is clear from (3)-(5) that (R0, R1) can be converted into (O0,OR). On the other 
hand, from (4), we obtain  
R0 = O01 + O0 .                                                                 (16) 
Combining with (3) and (5), we obtain 
R1 = (O0)(OR)1 + (O0)(OR).                                                       (17) 
Thus (O0, OR) can be converted into (R0, R1). Therefore (O0, OR) and (R0, R1) can be 
converted into each other. Furthermore, from (6)-(8), we see that (R0, R1) can be converted to 
the measures (R0, RD), (R0, RR) and (R0, AP), and vice versa. As a result, the measures (R0, RD), (R0, RR), (O0, OR) and (R0, AP) can be converted, i.e. obtained, from one another.   
 
Similarly, from (12)-(15), we see that the measures of (baseline, treatment effect) as function 
of the model parameters 𝜋, {O0(𝜋), OR(𝜋)}, {R0(𝜋), RD(𝜋)}, {R0(𝜋), RR(𝜋)} and {R0(𝜋), AP(𝜋)}, are convertible from one another. Because R�0 = R0(𝜋�), O�0 = O0(𝜋�), OR� = OR(𝜋�), RD� = RD(𝜋�), RR� = RR(𝜋�) and AP� = AP(𝜋�), the ML estimates, (R�0, RD� ), (R�0, RR� ), (O�0, OR� ) and (R�0, AF�), are convertible with one another. Therefore the distributions 




To obtain confidence regions of (R0, RD), (R0, RR), (O0, OR) and (R0, AP), we consider the 
logarithm of (O0, OR) , i.e. {log(O0), log(OR)}, as an additional measure of (baseline, 
treatment effect). Because the logarithm is a monotonic function, {log(O0), log(OR)} is 
convertible with any other measure of (baseline, treatment effect), and so is its ML estimate {log(O�0), log(OR� )} with the ML estimate of any other measure, and similarly for the 
distribution of {log(O�0), log(OR� )} and its corresponding confidence region.  
 
Because log(O0) and log(OR) range from  −∞ to +∞, the ML estimate {log(O�0), log(OR� )} is 
fairly normal even for finite sample (e.g. Lindsey, 1996) and thus the corresponding 
confidence region can be well approximated by an ellipse. Due to the convertibility of 
confidence regions, we can convert the elliptical confidence region of {log(O0), log(OR)} to 
non-elliptical confidence regions of (O0, OR), (R0, RD), (R0, RR) and (R0, AP). 
 
In the next section, we shall describe the procedure of obtaining point estimates and confidence 
regions of measures of (baseline, treatment effect). 
 
4 Procedure for obtaining confidence regions of (baseline, treatment effect) 
4.1 Approximate distributions for the ML estimates of baseline and 
treatment effect 
First we draw p from the normal distribution 𝑝~N(𝜋� , Σ�). Second, we replace 𝜋 by the obtained 
p in formulas (11) and (12) to get {O0(𝑝), OR(𝑝)} which approximates (O�0, OR� ). We iterate 
the procedure, 1000 times in this article, to get 1000 pairs of values of (O�0, OR� ). All these 1000 
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pairs form an approximate (joint) distribution of (O�0, OR� ). All values of O�0 in those 1000 pairs 
form an approximate (marginal) distribution of O�0. All values of OR�  in those 1000 pairs form 
an approximate (marginal) distribution of OR� .  Similarly, we obtain the distributions of other 
measures of baseline and treatment effect.  The approximate distributions for (O�0, OR� ), O�0 and OR�   are presented in Figure 1; those for (R�0, RD� ), R�0 and RD�  in Figure 2; those for (R�0, RR� ) 
and RR�  in Figure 3; those for (R�0, AF� ) and AF�  in Figure 4. 
 
4.2 Confidence regions of (baseline, treatment effect) 
By taking logarithm of the 1000 values of �O�0, OR��, O�0 and OR� , we obtain the distributions of {log(O�0), log(OR� )}, log(O�0), log(OR� ), which are presented in Figure 5. From the distribution 
of {log(O�0), log(OR� )}, we calculate the mean and covariance matrix and then construct the 
following normal distribution  
N ��0.120.68� , � 0.11 −0.11−0.11 0.21 ��. 
From this normal distribution, we obtain the ellipse formula 
{log(O0) − 0.12 log(OR) − 0.68} � 0.11 −0.11−0.11 0.21 � � log(O0) − 0.12log(OR) − 0.68� = 𝜒22(1 − 𝛼) 
from which we obtain the (1 − 𝛼) confidence region of {log(O0), log(OR)}, which is plotted 
in Figure 5. Now we convert this elliptical confidence region into non-elliptical confidence 
regions for other measures of (baseline, treatment effect) by the following procedure: a) 
converting {log(O0), log(OR)} to (O0, OR), b) using formulas (16) and (17) to obtain (R0, R1), 
and c) using formulas (6)-(8) to obtain (R0, RD), (R0, RR) and (R0, AP). 
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The 50% and 95 % confidence regions for (O0, OR), (R0, RD), (R0, RR) and (R0, AP) are 
shown in Figures 1-4 respectively. 
 
4.3 Confidence intervals of treatment effect alone 
Here we are going to calculate the confidence intervals of measures of treatment alone in order 
to compare them with the confidence regions of measures of (baseline, treatment effect) above. 
From (5)-(8) or (12)-(15), we see that the measures of treatment effect, OR, RD, RR and AF, 
are not convertible from one another, except for RR and AF. Hence we need to use distribution 
of the ML estimate of each measure of treatment effect to obtain (1 − 𝛼) confidence interval 
of the measure. We obtain that the 95 % confidence interval of OR is (0.79, 4.78), that for RD 
is (−0.05, 0.36), that for RR is (0.92, 1.92), and that for AF is (−0.09, 0.48). These confidence 
intervals are also presented in Table 3. See Wang et al. (2014a) for interval estimation of the 
marginal and conditional measures of treatment effect and Wang et al. (2014b) for properties 
of the ML estimate of RD based on logistic model.  
 
4.4 Comparison between confidence regions of (baseline, treatment effect) and 
confidence intervals of treatment effect 
The confidence region of a measure of (baseline, treatment effect) indicates possible values for 
the measure at the (1 − 𝛼) confidence level. Statistically, all the confidence regions for (O0, 
OR), (R0, RD), (R0, RR) and (R0, AF) are equivalent: each point of a confidence region can be 
converted to a unique point of another confidence region. Use of a specific confidence region 
is entirely determined by the specific medical context. 
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The confidence interval of a measure of treatment effect indicates possible values for the 
measure at certain (1 − 𝛼) confidence level regardless of values for baseline. For instance, the 
confidence interval of RD in Table 3 indicates possible values for RD, i.e. (−0.05, 0.36), at the 
95 % confidence level, regardless of values for R0.  
 
If we interpret the confidence interval of a measure of treatment effect together with a value of 
a measure of baseline, we may get misleading conclusion. For instance, it is misleading to 
claim a 95 % confidence interval (−0.05, 0.36) of RD at a baseline risk R0 = 0.68, because, at 
the upper limit of the confidence interval, RD + R0= 0.36 + 0.68 is larger than one. 
 
5 Conclusions and discussions 
To learn significance of treatment effect to the population, one needs to report both baseline 
and treatment effect. Because the ML estimate of a measure of baseline is highly correlated 
with that of a measure of treatment effect, one needs to report baseline and treatment effect 
jointly. To our knowledge, little is seen in the literature of joint estimation of even one measure 
of (baseline, treatment effect) by a model in observational studies. 
 
In this article, we express common measures of (baseline, treatment effect) in terms of the 
conditional risk of outcome given treatments and covariates, which is then expressed by a 
logistic model. Therefore we can use only one logistic model to control confounding covariates 
and estimate these measures together. Because the expressions of these measures are smooth 
bounded functions of the logistic model parameters, the performance of the logistic model in 
estimating confidence region is determined by the performance of the logistic model in 
estimating its own model parameters. 
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Because parameters of a logistic model have good asymptotic normality, we use approximate 
normal distribution of the ML estimates of the logistic model parameters to generate 
approximate distributions of the ML estimates of various measures of (baseline, treatment 
effect) and then use the obtained distributions to calculate confidence regions of these 
measures. Our method can be easily implemented by any software that generates normal 
distribution in comparison to high complexity of the normal approximation method and the 
bootstrap method for estimating confidence regions of measures of (baseline, treatment effect). 
 
To conclude the article, we give two immediate extensions of our approach to estimation of 
confidence regions for measures of (baseline, treatment effect). First, we can replace the 
covariate-based logistic model by the propensity score-based logistic model to obtain the 
confidence regions. Due to a relatively small sample size and relatively few confounding 
covariates of the illustrative example, we have used the covariate-based logistic model to 
control the confounding covariates. When sample is large with many covariates, one 
sometimes uses the propensity score of treatment given covariates to control confounding 
covariates (Rosenbaum and Rubin, 1983; Rosenbaum, 1995). In this case, we can obtain 
confidence regions for measures of (baseline, treatment effect) by using the propensity score-
based logistic model and considering the propensity score as the sole covariate in the model. 
 
Second, we can use other models than logistic model to obtain confidence regions for measures 
of (baseline, treatment effect). For instance, sometimes, one finds that some model, e.g. log-
linear model, describes the data better than logistic model. In this case, we can obtain 
confidence regions for measures of (baseline, treatment effect) by replacing the logistic model 
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Table 1 Eradication of Helicobacter pylori among Vietnamese children: successful 
eradications / total patients on levels of the covariates 𝑥1 -- 𝑥4 for high respective low doses of 


























Covariates  Treatment 
𝑥𝟏 (age) 𝑥2 (gender) 𝑥3 (geographic) 𝑥4 (resistance) 𝑧 = 1(high)   𝑧 = 0(low) 
       
0 0 0 0  0/3 3/4 
0 0 0 1  1/1 3/4 
0 0 1 0  8/8 6/7 
0 0 1 1  1/1  
0 1 0 0  2/3 1/5 
0 1 0 1  1/2 2/4 
0 1 1 0  3/3 3/4 
0 1 1 1   1/1 
1 0 0 0  3/8 1/2 
1 0 0 1  1/1 3/3 
1 0 1 0  6/6 1/1 
1 0 1 1  3/3 0/1 
1 1 0 0  5/8 2/7 
1 1 0 1  6/9 1/2 
1 1 1 0  0/2 0/2 
1 1 1 1  1/1 0/3 
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Parameters   α β θ1 θ2 θ3 θ4 θ5 θ6 
          
Estimates 1.19 −0.87 −0.57 −1.82 0.10 0.55 1.96 2.18 
          
Covariance matrix         
         
α   0.64 −0.53 −0.12 −0.42 −0.32 −0.13 0.47 0.29 
          
β   −0.53 1.06 −0.14 0.45 0.31 0.10 −0.89 −0.67 
          
θ1   −0.12 −0.14 0.37 −0.04 0.00 −0.05 0.03 0.05 
          
θ2   −0.42 0.45 −0.04 0.69 0.05 −0.01 −0.69 −0.05 
          
θ3   −0.32 0.31 0.00 0.05 0.72 0.06 −0.07 −0.71 
          
θ4   −0.13 0.10 −0.05 −0.01 0.06 0.39 −0.10 −0.04 
          
θ5   0.47 −0.89 0.03 −0.69 −0.07 −0.10 1.40 0.32 
          
θ6   0.29 −0.67 0.05 −0.05 −0.71 −0.04 0.32 1.86 
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 ML estimate 50 % and 95 % Confidence intervals 
Baseline measure   R0 0.53 (0.37, 0.48, 0.58, 0.68) 
   O0 1.13 (0.58, 0.92, 1.38, 2.13) 
   
Effect measure   
OR 2.11 (0.79, 1.45, 2.67, 4.78) 
   
RR 1.33 ( 0.92, 1.15, 1.47, 1.92) 
   
RD 0.17 (−0.05, 0.09, 0.23, 0.36) 
   
AF 0.25  (−0.09, 0.13, 0.32, 0.48) 
   
 1 
Figure 1 (a) The scatterplot for approximate distribution of the ML estimate (O�0, OR� ), and the 
50% and 95% confidence regions of (O0, OR). (b)  Approximate distribution for the ML 



























Figure 2 (a) The scatterplot for approximate distribution of the ML estimate (R�0, RD� ), and the 
50% and 95% confidence regions of (R0, RD). (b)  Approximate distribution for the ML 



























Figure 3 (a) The scatterplot for approximate distribution of the ML estimate (R�0, RR� ), and the 
50% and 95% confidence regions of (R0, RR). (b)  Approximate distribution for the ML 

























Figure 4 (a) The scatterplot for approximate distribution of the ML estimate (R�0, AF� ), and the 
50% and 95% confidence regions of (R0, AF). (b)  Approximate distribution for the ML 

























Figure 5 (a) The scatterplot for approximate distribution of the ML estimate �log(O�0�,  log(OR� )}, and the 50% and 95% confidence regions of {log(O0), log(OR)}. (b)  Approximate 
distribution for the ML estimate log(O�0). (c)  Approximate distribution for the ML estimate log(OR� ). The point estimate of {log(O0), log(OR)} is equal to (0.12, 0.75).   
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